Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $56M (up 18.1% year over year) with net income of −$23M.
Q3 2025 key financials · XBRL
- Revenue
- $56M
- +18.1% YoY · +7.0% QoQ
- Net income
- −$23M
- −324.2% YoY · +17.0% QoQ
- Operating margin
- -55.6%
- EPS (diluted)
- −$0.39
- −333.3% YoY · +15.2% QoQ
Source: XBRL data from the Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 10-Q on SEC EDGAR. USD.
Vanda Pharmaceuticals Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $56.3M, up 18% from $47.7M YoY
- Fanapt best performer: sales $31.2M, up 31% YoY
- HETLIOZ weakest growth: sales $18.0M, up 1% YoY
- PONVORY sales $7.0M, up 20% YoY
- HETLIOZ headwinds: generic competition and elevated specialty-pharmacy inventory; Medicare Part D redesign risk to future revenue
Risk Factors
- Risk Factors section not provided in the submitted filing text
- No basis to identify newly added or materially updated risks versus the 10-K
- No regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks disclosed in provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vanda Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.